Phase IIb Protocol 011 Safety Analysis at Week 96: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction

July 18-21, 2021; Virtual
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 20, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings